**Supplementary Table 1.** List of mAbs used for flow cytometry

|  |  |  |  |
| --- | --- | --- | --- |
| **mAb-Fluorochrome** | **Clone** | **Company** | **Catalog** |
| CD127-PE-Cy7 | HIL-7R-M21 | BD Pharmingen™ | 560822 |
| CD183 (CXCR3)-PE-Cy5  | 1C6/CXCR3 | BD Pharmingen™ | 551128 |
| CD194 (CCR4)-BV 421 | 1G1 | BD Horizon™ | 562579 |
| CD196 (CCR6)-PE | 11A9 | BD Pharmingen™ | 551773 |
| CD25-BV 786  | M-A251 | BD Horizon™ | 563701 |
| CD25-PE | M-A251 | BD Pharmingen™ | 555432 |
| CD28-APC | CD28.2 | BD Pharmingen™ | 559770 |
| CD31-APC-Cy7 | WM59 | BD Pharmingen™ | 563653 |
| CD38-PE | HIT2    | BD Pharmingen™ | 555460 |
| CD39-APC | TU66 | BD Pharmingen™ | 560239 |
| CD39-BV 711 | TU66 | BD Horizon™ | 563680 |
| CD3-Alexa Fluor 700 | UCHT1 | BD Pharmingen™ | 557943 |
| CD3-BV 786 | UCHT1 | BD Horizon™ | 565491 |
| CD45RA-BV 650 | HI100 | BD Horizon™ | 563963 |
| CD45RA-PE-CF594 | HI100 | BD Horizon™ | 562298 |
| CD4-FITC | RPA-T4 | BD Pharmingen™ | 555346 |
| CD4-PE-Cy5 | RPA-T4 | BD Pharmingen™ | 555348 |
| CD57-BV 421 | NK-1 | BD Horizon™ | 563896 |
| CD73-BV 605 | AD2 | BD Horizon™ | 563199 |
| CD8-APC-R700 | SK1 | BD Horizon™ | 565192 |
| CD8-APC-H7 | SK1 | BD Pharmingen™ | 560179 |
| FoxP3-PE-CF594 | 236A/E7  | BD Horizon™ | 563955 |
| Helios-FITC | 22F6 | Biolegend | 137214 |
| HLA-DR-BV 605 | G46-6 | BD Horizon™ | 562845 |

**Supplementary Table 2**. Effect of statins treatment in immunological markers. To assess the potential contribution of statins treatment on Tregs, we excluded statins users from our study groups.

|  |  |  |
| --- | --- | --- |
|  | **Study groups excluding statins users** |  |
|  % **Mean±SD**  | **HIV+CAD+  (n=19)** | **HIV+CAD- (n=33)** | **HIV-CAD+ (n=25)** | **HIV-CAD- (n=24)** | ***p-*values** |
| **Total Treg**  | 4.3±2.8 a, b, c | 2.9±1.6 a | 2.7±0.9 b | 2.3±1.5 c | 0.003 |
| **Naïve Treg**  | 17.7±10.7 a | 11.1±7.8 a | 13.1±7.8 | 17.3±16.6 | 0.09 |
| **CM Treg**  | 74.9±12.4 b, c | 74.1±2.2 d, e  | 65.9±10.9 b, d | 60.1±20.2 e | 0.001 |
| **EM Treg**  | 2.7±4.7 a, b, c | 7.8±8.6 a | 9.8±7.4 b | 9.5±8.5 c | 0.01 |
| **TD Treg**  | 4.7±3.9 a, b, c | 6.9±5.1 a, d, e  | 11.2±5.8 b, d | 12.8±7.9 c, e | <0.0001 |
| **CD31+ Treg**  | 0.3±0.2 c | 0.3±0.2 | 0.3±0.1 c, f | 0.2±0.2 f | 0.17 |
| **Helios+ Treg**  | 2.7±1.0 a, c | 1.9±1.0 a | 2.0±0.7 c, f | 1.6±1.1 f | 0.04 |
| **CD31+Helios+ Treg**  | 0.2±0.1 c | 0.2±0.1 | 0.2±0.1 c | 0.1±0.1 | 0.32 |
| **CD39+ Treg**  | 43.3±24.9 a | 57.9±22.9 a, d | 43.7±20.5 d | 45.9±24.6 | 0.05 |
| **CD73+ Treg**  | 1.3±1.3 a, b, c | 3.5±4.9 a | 4.6±3.8 b | 4.1±3.1 c | 0.04 |
| **CD39+CD73+ Treg**  | 0.5±0.4 a, b, c | 1.6±1.8 a | 1.6±1.5 b | 1.8±1.7 c | 0.03 |
| **Memory CCR6+ Treg**  | 13.1±8.8 b, c  | 13.0±11.7 e | 8.6±10.9 b | 4.8±8.2 c, e | 0.01 |
| **Memory CXCR3+ Treg**  | 4.9±3.7 | 6.8±4.7 d, e | 4.1±4.4 d | 3.4±3.5 e | 0.01 |
| **Memory CCR4+ Treg** | 63.6±26.7 a, b, c | 55.7±17.3 a | 50.3±14.9 b | 47.8±23.2 c | 0.02 |
| **CD4+HLA-DR+**  | 4.5±4.1 a, b, c | 9.9±7.2 a | 9.0±6.7 b | 9.6±3.9 c | 0.01 |
| **CD4+HLA-DR+CD38+**  | 1.1±0.9 | 1.9±3.2 | 1.3±0.8 | 1.2±1.2 | 0.35 |
| **CD8+HLA-DR+**  | 3.2±2.8 a, b, c | 6.9±5.8 a | 7.2±6.8 b | 9.9±7.7 c | 0.006 |
| **CD8+HLA-DR+CD38+**  | 1.2±0.9 c | 1.8±1.7 | 1.7±1.4 c | 2.2±2.0 | 0.20 |

***Nota bene:*** Results are shown as mean ± standard deviation (SD). comparison of the four groups was done by Kruskal-Wallis test. Significant differences (p < 0.05 following t-test) are mentioned as follow:

a: HIV+CAD+ *vs* HIV+CAD-; b:HIV+CAD+ *vs* HIV-CAD+; c:HIV+CAD+ *vs* HIV-CAD-;
d:HIV+CAD- *vs* HIV-CAD+; e: HIV+CAD- *vs* HIV-CAD-; f:HIV-CAD+ *vs* HIV-CAD-.

**Supplementary Table 3**. Effect of ART regimen in immunological markers of HIV-infected individuals regardless of CAD status.

|  |  |
| --- | --- |
|   | **HIV+ regardless CAD status** |
|   % **Mean±SD** | **PI****(n=36)** | **INSTI****(n=15)** | **NNRTI****(n=14)** | **PI+NNRTI and/or INSTI****(n=15)** | ***p*-values** |
| **Total Treg**  | 4.21±2.48 b | 2.80±1.23 | 3.02±1.08 b | 3.97±1.83 | 0.16 |
| **Naïve Treg**  | 15.62±9.63 | 15.42±9.09 | 12.76±10.41 | 12.74±9.98 | 0.48 |
| **CM Treg**  | 75.30±10.68 | 72.25±16.51 | 75.28±10.38 | 76.49±11.82 | 0.97 |
| **EM Treg**  | 3.72±4.98 | 5.14±8.82 | 5.94±5.62 | 5.98±8.79 | 0.16 |
| **TD Treg**  | 5.33±3.82 | 7.17±6.72 | 6.03±2.96 | 4.79±3.43 | 0.62 |
| **CD31+ Treg**  | 8.99±4.74 | 7.39±2.43 | 8.53±2.68 | 7.42±1.87 | 0.56 |
| **Helios+ Treg**  | 74.47±8.99 | 72.24±8.23 | 70.71±7.15 | 73.78±7.38 | 0.46 |
| **CD31+Helios+ Treg**  | 5.92±3.97 | 5.64±1.81 | 6.28±2.01 | 5.40±1.19 | 0.52 |
| **CD39+ Treg**  | 53.42±23.70 | 43.67±18.62 | 53.45±22.08 | 55.43±28.33 | 0.4 |
| **CD73+ Treg**  | 2.90±4.62 | 2.71±2.95 | 2.53±3.24 | 1.59±1.61 | 0.78 |
| **CD39+CD73+ Treg**  | 1.25±1.71 | 1.27±1.19 | 0.97±1.04 | 1.12±1.56 | 0.92 |
| **Memory CCR6+ Treg**  | 16.79±11.75 | 14.61±15.05 | 13.77±16.72 | 16.11±12.35 | 0.41 |
| **Memory CXCR3+ Treg**  | 6.78±3.86 b | 8.33±5.65 | 10.99±6.21 b | 7.081±4.29 | 0.15 |
| **Memory CCR4+ Treg** | 67.60±22.24 | 62.80±21.62 | 64.44±13.83 | 72.17±19.59 | 0.41 |
| **CD4+HLA-DR+**  | 6.79±6.57 | 5.90±4.60 | 7.94±5.73 | 6.49±5.75 | 0.64 |
| **CD4+HLA-DR+CD38+**  | 1.10±0.72 a | 0.63±0.48 a, d, e | 1.54±1.18 d | 1.69±1.37 e | 0.008 |
| **CD8+HLA-DR+**  | 4.28±4.17 | 5.83±6.51 | 4.57±4.15 | 4.11±3.40 | 0.94 |
| **CD8+HLA-DR+CD38+**  | 1.47±1.61 | 1.20±1.19 | 1.19±0.84 | 1.30±0.88 | 0.83 |

PI: protease inhibitor, INSTI: integrase strand transfer inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitors.

***Nota bene:*** Results are shown as mean ± standard deviation (SD). comparison of the four groups was done by Kruskal-Wallis test. Significant differences (p < 0.05 following t-test) are mentioned as follow:

a: PI *vs* INSTI; b:PI *vs* NNRTI; c:PI *vs* PI+NNRTI and/or INSTI;
d:INSTI *vs* NNRTI; e: INSTI *vs* PI+NNRTI and/or INSTI; f:NNRTI *vs* PI+NNRTI and/or INSTI.